___

• 1. Matteoni CA, Younossi ZM, Gramlich T, et al. Non-alcoholic fatty liver disease. Gastroenterology 116: 1413-9, 1999. 2. Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 13: 17-30, 2002. 3. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 34: 255-62, 2002. 4. Okolo P, Diehl AM. Non-alcoholic steatohepatitis and focal fatty liver. Sleisenger & FordtranÕs Gastrointestinal and Liver Disease (Feldman M, Sleisenger MH, Scharschmidt BF, eds.). WB Saunders, Philadelphia, pp 1215-20, 1998. 5. Oliver FWJ, Christoph PD. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29: 495-501, 1998. 6. Tilg H, Diehl AM. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 343: 1467-76, 2000. 7. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 126: 137-45, 1997. 8. Yang S, Lin H, Diehl AM. Fatty liver vulnerability to endotoxininduced damage despite NF-kB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 281: 382- 92, 2001.
• 9 Diehl AM. Nonalcoholic steaotohepatitis. Semin Liver Dis 19: 221- 9, 1999. 10 Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic-induced steatohepatitis: a pilot study. Hepatology 23: 1464-7, 1996. 11 Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor-a in alcohol-induced liver injury in mice. Gastroenterology 117: 942-52, 1999. 12 Lentsch AB, Yoshidome H, Kato A, et al. Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. Hepatology 30: 1448-53, 1999. 13 Diehl AM. Nonalcoholic Steatosis and Steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 282: 1-5, 2002. 14 West DA, James NH, Cosulich SC, et al. Role for tumor necrosis factor a receptor 1 and interleukin-1 receptor in the suppression of mouse hepatocyte apoptosis by the peroxisome proliferator nafenopin. Hepatology 30: 1417-24, 1999. 15 Fiatarone JR, Coverdale SA, Batey RG, et al. Non-alcoholic steatohepatitis: impaired antipyrine metabolism and hypertriglyceridemia may be clues to its pathogenesis. J Gastroenterol Hepatol 6: 585-90, 1991. 16 Huang YS, Wu JC, Chang FY, et al. Interleukin-8 and alcoholic liver disease. Chung Hua I Hsueh Chih 62: 395-401, 1999. 17 Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122: 274-80, 2002. 18 Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48: 148-9, 2001. 19 Vromen A, Spira RM, Bercovier H, et al. Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. JPEN J Parenter Enteral Nutr 21: 233-4, 1997. 20 Yang SQ, Liu HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of the steatohepatitis. Proc Natl Acad Sci USA 94: 2557-62, 1997. 21 Jarvelainen HA, Fang C, Ingelman-Sundberg M, et al. Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. J Hepatol 32: 1026-30, 2000. 22 Memon RA, Grunfeld C, Feingold KR. TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat Med 7: 2-3, 2001. 23 Schafer C, Schips I, Landig J, et al. Tumor-necrosis-factor and interleukin-6 response of peripheral blood monocytes to low concentrations of lipopolysaccharide in patients with alcoholic liver disease. Z Gastroenterol 33: 503-8, 1995.